Cell Therapy That Retrains the Immune System to Stop Multiple Sclerosis

The project data does not include licensing fees or therapy cost estimates. However, cell therapies typically require per-patient manufacturing of personalized dendritic cells, which involves significant production infrastructure. Any licensing discussion would need to go through Universiteit Antwerpen as the coordinating institution.

The consortium developed standardized manufacturing and training protocols across multiple clinical sites in 4 countries (Belgium, Germany, Spain, Netherlands). They created training programs for neurologists and clinical staff, and standardized MRI monitoring via icometrix. This multi-site coordination demonstrates early scalability, though full commercial-scale manufacturing would require further development.

As a publicly funded EU project (RIA scheme) with 9 partners, IP is likely shared among consortium members according to the grant agreement. The coordinating institution is Universiteit Antwerpen. Companies interested in licensing should contact the university's technology transfer office. Based on available project data, specific patent filings are not detailed.

The project explicitly states that all regulatory approvals were already in place before clinical trials began. They completed dose-escalation studies and safety assessments for two administration routes. This regulatory groundwork significantly de-risks the path to further clinical development.

The project completed Phase I/II-level clinical trials including dose-escalation and safety/proof-of-concept studies. They identified the maximum tolerated dose and compared two administration routes. However, larger Phase III trials would still be needed before market authorization, which typically requires additional years of development and significant investment.

This antigen-specific approach is designed to target only the damaging immune reactions causing MS, without suppressing the entire immune system. This means it could potentially complement existing treatments by preserving protective immunity against infections and cancer. The project used standardized MRI monitoring compatible with existing clinical neuroimaging infrastructure.

Yes — the project established consented biobanking, data safeguarding, and accessibility protocols specifically to support future efforts in MS therapy. Coordinated patient monitoring and centralized immunomonitoring data from both clinical trials are designed for cross-comparison and future use.